Evaxion Biotech A/S (NASDAQ:EVAX) Price Target Cut to $6.00 by Analysts at Lake Street Capital

Evaxion Biotech A/S (NASDAQ:EVAX) had its target price decreased by investment analysts at Lake Street Capital from $35.00 to $6.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital’s price objective would indicate a potential upside of 100.67% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Monday.

Evaxion Biotech A/S Stock Performance

NASDAQ:EVAX opened at $2.99 on Tuesday. The firm’s fifty day moving average price is $4.69 and its 200 day moving average price is $10.53. Evaxion Biotech A/S has a 1-year low of $2.22 and a 1-year high of $23.70. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. The firm has a market cap of $3.50 million, a price-to-earnings ratio of -2.06 and a beta of -0.28.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S as of its most recent filing with the SEC. Hedge funds and other institutional investors own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.